West Pharmaceutical Services, Inc. (WST) Expected to Announce Quarterly Sales of $415.53 Million
Brokerages expect West Pharmaceutical Services, Inc. (NYSE:WST) to announce $415.53 million in sales for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for West Pharmaceutical Services’ earnings, with the lowest sales estimate coming in at $411.50 million and the highest estimate coming in at $418.00 million. West Pharmaceutical Services reported sales of $382.30 million in the same quarter last year, which indicates a positive year over year growth rate of 8.7%. The company is scheduled to announce its next quarterly earnings results on Thursday, February 15th.
According to Zacks, analysts expect that West Pharmaceutical Services will report full-year sales of $415.53 million for the current fiscal year. For the next financial year, analysts anticipate that the company will post sales of $1.73 billion per share, with estimates ranging from $1.71 billion to $1.74 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow West Pharmaceutical Services.
West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, October 26th. The medical instruments supplier reported $0.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.53 by $0.14. The business had revenue of $398.20 million for the quarter, compared to analyst estimates of $386.02 million. West Pharmaceutical Services had a return on equity of 14.47% and a net margin of 12.12%. The company’s quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.53 EPS.
Institutional investors have recently modified their holdings of the stock. Acrospire Investment Management LLC acquired a new position in shares of West Pharmaceutical Services during the 2nd quarter worth approximately $113,000. Citigroup Inc. raised its position in shares of West Pharmaceutical Services by 95.1% during the 2nd quarter. Citigroup Inc. now owns 1,569 shares of the medical instruments supplier’s stock worth $148,000 after purchasing an additional 765 shares during the last quarter. Grandfield & Dodd LLC acquired a new position in shares of West Pharmaceutical Services during the 3rd quarter worth approximately $201,000. Wolverine Trading LLC acquired a new position in shares of West Pharmaceutical Services during the 2nd quarter worth approximately $200,000. Finally, Nomura Holdings Inc. acquired a new position in shares of West Pharmaceutical Services during the 2nd quarter worth approximately $201,000. Hedge funds and other institutional investors own 93.26% of the company’s stock.
Shares of West Pharmaceutical Services (WST) opened at $99.11 on Friday. The company has a market capitalization of $7,360.00, a P/E ratio of 41.53, a PEG ratio of 2.05 and a beta of 1.14. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.87 and a current ratio of 2.59. West Pharmaceutical Services has a 52 week low of $77.97 and a 52 week high of $103.36.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with MarketBeat.com's FREE daily email newsletter.